PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
May 20, 2026American Journal of Respiratory and Critical Care Medicine

A76-22 Sex Differences in Clinical Outcomes Among Adults With Cystic Fibrosis After Initiation of Elexacaftor/Tezacaftor/Ivacaftor: Analysis From a Multi-center Prospective Study

View Full Paper
Ask AI
Bookmark
Share

Authors

HUH UpretiSPS ParkSAS Abid

Discussion

Loading...

Member takes

Overview

Randomized trial compares clinical outcomes between males and females with cystic fibrosis, indicating nuanced sex-related differences.

Key Points

  • This study compares clinical outcomes between male and female adults with cystic fibrosis after initiating a specific treatment regimen.
  • Multicenter prospective study of adults with cystic fibrosis >12 years old on CFTR modulators.
  • Data collected at various time points: prior, 1, 3, 6, 18, and 30 months after treatment initiation.
  • Outcomes analyzed included FEV1, BMI, CFQ-R score, sweat chloride, and prevalence of Pseudomonas aeruginosa.
  • No significant sex differences in FEV1, BMI, or CFQ-R changes after 30 months.
  • Females had a greater reduction in sweat chloride compared to males (mean difference -46.2 mmol/L vs -38.5 mmol/L, p<0.001).
  • Males exhibited a lower incidence of pulmonary exacerbations among those with baseline FEV1 <50 (rate ratio=0.42; 95% CI 0.19, 0.93).

Cite This Study

Upreti et al. (2026) studied this question.

synapsesocial.com/papers/6a0d4f92f03e14405aa9aec0https://doi.org/10.1093/ajrccm/aamag162.2130
View Full Paper
Ask AI
Bookmark
Share